WebDoctor Encyclopedia

Gynecologic Ovarian

Serous borderline ovarian tumour

Serous borderline ovarian tumours are epithelial growths that sit between benign cysts and invasive cancer. They often affect younger women, can usually be treated with fertility-sparing surgery, and have an excellent long-term outlook, though they can recur.

Medically reviewed Last reviewed October 20, 2026

What is a serous borderline ovarian tumour?

A serous borderline ovarian tumour (SBOT) is an ovarian growth that sits between a harmless cyst and an ovarian cancer. Its cells look more active than those of a benign cyst, but they do not invade the surrounding tissue in the way a true cancer does. Doctors also call these tumours “tumours of low malignant potential” or atypical proliferative serous tumours.

“Serous” describes the type of cell. These cells resemble the lining of the fallopian tube and produce a watery fluid. Serous tumours are the most common kind of borderline ovarian tumour.

Unlike most ovarian cancers, SBOTs often affect younger women, many of whom have not yet completed their families. About a third of women are under 40 at diagnosis. This is why fertility-sparing surgery is a central part of treatment planning (Carbonnel et al., 2021).

The outlook is very good. Most women are cured by surgery alone, and deaths are rare. However, the tumour can come back, especially in the remaining ovary, and a small number of cases later turn into a low-grade serous cancer. Long-term follow-up is therefore recommended (Prat and De Nictolis, 2002).

1. Key facts at a glance

Feature Details
Type of tumour Borderline (low malignant potential) epithelial tumour of the ovary
Also called Atypical proliferative serous tumour; tumour of low malignant potential
How common Borderline tumours are 10-20% of epithelial ovarian tumours; about half are serous
Typical age Usually 30-50; a third under 40
Both ovaries Involved in roughly a third of cases
Stage at diagnosis About two-thirds confined to the ovary or ovaries
Main treatment Surgery, often preserving fertility
Chemotherapy Rarely needed
Outlook Excellent; survival over 95% at 10 years in most series

2. Types of serous borderline tumour

Type Features Behaviour
Typical (usual) SBOT Branching papillae lined by layered cells Very favourable
Micropapillary variant Long, thin papillae arising directly from thick stalks More often bilateral and associated with implants; still mostly favourable
SBOT with microinvasion Tiny foci of invasion under about 5 mm Behaves much like typical SBOT

Implants outside the ovary

In about a third of women, small deposits called implants are found on the lining of the pelvis or abdomen.

Implant type Meaning
Non-invasive implants Deposits on the surface; usually behave in a benign way
Invasive implants Deposits that destroy underlying tissue; now classed as low-grade serous carcinoma

The distinction matters: in a long-term study, poor outcomes were seen almost only in women whose implants were invasive (Prat and De Nictolis, 2002).

How it compares with other ovarian growths

Growth Invades tissue? Usual treatment Outlook
Benign serous cystadenoma No Removal of the cyst or ovary Cured
Serous borderline tumour No (or only tiny foci) Surgery, often fertility-sparing Excellent
Low-grade serous carcinoma Yes Surgery, then hormone therapy or chemotherapy Slow-growing but can recur
High-grade serous carcinoma Yes Surgery and chemotherapy Serious

3. Causes and risk factors

The cause of SBOT is not fully understood. Many experts think these tumours start from cells of the fallopian tube or from small inclusion cysts in the ovary.

Factor Notes
Age Mainly women of reproductive age and in their 40s
Infertility Some studies show a modest link
Not having children Associated with ovarian tumours in general
Use of the contraceptive pill May lower the risk

Gene changes

Gene change Notes
KRAS mutation Common
BRAF mutation Common; may be linked with a lower risk of progression to cancer
ERBB2 and other changes Seen in a minority

These changes occur only in the tumour and are not inherited. SBOT is not usually linked with BRCA gene mutations.

4. How does it look

On the ovary

Feature Description
Shape A cyst with fine, frond-like growths inside or on the surface
Size Often 5-10 cm, but can be larger
Contents Clear, watery fluid
Surface growths Present in some; linked with a higher chance of implants
Both sides One or both ovaries may be affected

On scans

Transvaginal ultrasound usually shows a cyst with papillary projections, which are small solid bumps on the inner wall. Blood flow may be seen within these projections. MRI helps to tell a borderline tumour from a benign cyst or invasive cancer and can show whether the other ovary is involved. CT is used when spread in the abdomen is suspected.

Under the microscope

Feature Description
Papillae Branching, tree-like folds lined by serous cells
Cell layering Cells pile up in several layers and bud off into the cyst
Atypia Mild to moderate
Invasion Absent, or limited to tiny microinvasive foci
Psammoma bodies Small calcified spheres are common

5. Symptoms

Many SBOTs cause no symptoms and are found by chance on an ultrasound done for another reason.

Common symptoms

  • Pain or discomfort in the lower abdomen or pelvis
  • Bloating or a feeling of fullness
  • A swelling of the abdomen
  • Changes in periods

Less common symptoms

Symptom What it may mean
Sudden severe pain Twisting (torsion) or rupture of the cyst
Passing urine more often Pressure on the bladder
Constipation Pressure on the bowel
Fluid in the abdomen Can occur with implants
Difficulty getting pregnant Found during fertility investigations

When to seek medical advice

See a doctor if you have bloating, pelvic pain, feeling full quickly or needing to pass urine more often on most days for more than a few weeks. Seek urgent care for sudden severe pelvic pain.

6. Diagnosis

Test Purpose
Pelvic examination Checks for a mass
Transvaginal ultrasound Main test for describing the cyst
MRI Clarifies uncertain ultrasound findings
CA-125 blood test Often mildly raised; not specific
CT scan Looks for spread in the abdomen
Surgery and pathology The only way to confirm the diagnosis

A frozen section (quick examination of tissue during surgery) can suggest the diagnosis, but it sometimes under-calls or over-calls the tumour, so the final answer comes from the full laboratory report (Gershenson, 2017).

Staging

SBOTs are staged with the FIGO system for ovarian tumours.

Stage What it means
Stage I Confined to one or both ovaries
Stage II Spread within the pelvis
Stage III Implants in the abdomen or lymph node involvement
Stage IV Distant spread; very rare

7. Treatment

Treatment is planned by a gynaecological oncology team, ideally with a fertility specialist when relevant.

Surgery

Option Who it suits Notes
Ovarian cystectomy Young women, especially with tumours in both ovaries Keeps the most ovarian tissue; higher recurrence risk
Unilateral salpingo-oophorectomy Young women with one ovary affected Removes the affected ovary and tube
Total hysterectomy and both ovaries Women who have completed their families or are past the menopause Lowest recurrence risk
Staging procedures Most women Fluid washings, omentectomy and biopsies of the abdominal lining

Routine removal of lymph nodes is not recommended, because it does not improve survival (Gershenson, 2017). Surgery can often be done by keyhole (laparoscopic) methods.

Fertility-sparing surgery

Keeping the uterus and at least part of one ovary allows many women to conceive naturally. The trade-off is a higher chance of recurrence, usually as another borderline tumour in the remaining ovary, which can generally be treated with further surgery. In a French series of 65 women with more advanced SBOT treated conservatively, 58% had a recurrence, but 20 women went on to have 24 pregnancies (Gouy et al., 2021).

Chemotherapy and other treatment

Situation Approach
Stage I, completely removed No further treatment
Non-invasive implants Usually no further treatment
Invasive implants or low-grade serous carcinoma Treated as low-grade serous cancer, possibly with hormone therapy or chemotherapy

Pregnancy and fertility after treatment

Topic What to know
Trying to conceive Many women try soon after recovery, once follow-up scans are clear
Fertility treatment Ovarian stimulation and IVF have been used; plans are made with the cancer team
Egg or embryo freezing Can be discussed before surgery if both ovaries are affected
During pregnancy Ultrasound follow-up usually continues
After the family is complete Some women choose to have the remaining ovary removed

What treatment involves day to day

Stage What to expect
Keyhole surgery Often a day case or 1-2 nights in hospital
Open surgery Around 3-5 nights in hospital
Recovery Light activity within 1-2 weeks; full recovery in 4-6 weeks
Results The full pathology report usually takes 1-3 weeks

Side effects

Treatment Possible side effects
Keyhole surgery Shoulder-tip pain, bloating, small wound problems
Removal of one ovary Usually no change in hormones; fertility often maintained
Removal of both ovaries Immediate menopause if not already menopausal
Omentectomy Generally few long-term effects

8. Outlook (prognosis)

Situation Usual outcome
Stage I Close to 100% survival
Advanced stage with non-invasive implants Very good survival, though recurrence is more common
Invasive implants Outlook similar to low-grade serous carcinoma
After fertility-sparing surgery More recurrences, but survival is not reduced in most studies

Recurrence may appear many years after the first operation. Most recurrences are borderline tumours again, but a small proportion are low-grade serous carcinoma (Prat and De Nictolis, 2002).

Why recurrence is more common after fertility-sparing surgery

When an ovary or part of an ovary is kept, the remaining ovarian tissue can develop a new borderline tumour. This is especially likely after a cystectomy, where only the cyst is removed. Most of these recurrences are found on routine ultrasound before they cause symptoms, and they are usually treated with another operation. Women weigh this extra risk against the chance of natural pregnancy and of avoiding an early menopause, ideally after a detailed discussion with their surgeon.

9. Follow-up

Follow-up Purpose
Clinic review every 6 months for the first few years Checks symptoms and examination
Transvaginal ultrasound Especially important if an ovary was kept
CA-125 Helpful if it was raised at diagnosis
Yearly review afterwards Continued for at least 10 years in many centres
Completion surgery Sometimes discussed after childbearing is complete

10. Living with a serous borderline ovarian tumour

  • Attend follow-up scans, particularly if you still have ovarian tissue
  • Talk to a fertility specialist if you plan to have children
  • Ask about menopause symptom relief if both ovaries were removed
  • Report new pelvic pain or bloating without waiting for your next appointment
  • Seek support from ovarian cancer charities, which also help women with borderline tumours

11. Frequently asked questions

Question Answer
Is a borderline tumour cancer? Not quite; it is a low-risk tumour that does not usually invade
Will I need chemotherapy? Very rarely
Can I still have children? Often yes, with fertility-sparing surgery
Can it come back? Yes, mainly in a remaining ovary; it can usually be removed again
Can it turn into cancer? Occasionally, usually a slow-growing low-grade serous cancer
Is it inherited? Not usually
Is IVF safe afterwards? Many women have had successful treatment; discuss timing with your team
Do I need my lymph nodes removed? No, routine lymph node removal is not recommended
Will my periods stop? Not if at least part of one ovary is kept

12. Questions to ask your care team

  • Is my tumour the typical or micropapillary type?
  • Were there any implants, and were they invasive or non-invasive?
  • Can my fertility be preserved?
  • What is my risk of recurrence?
  • How often will I need scans, and for how long?
  • Should I consider further surgery once my family is complete?

Resources

  1. Carbonnel, M. et al. (2021) ‘Serous borderline ovarian tumor diagnosis, management and fertility preservation in young women’, Journal of Clinical Medicine, 10(18), 4233.
  2. Gershenson, D.M. (2017) ‘Management of borderline ovarian tumours’, Best Practice and Research Clinical Obstetrics and Gynaecology, 41, pp. 49-59.
  3. Gouy, S. et al. (2021) ‘Results after conservative surgery of stage II/III serous borderline ovarian tumors’, Annals of Surgical Oncology, 28(7), pp. 3597-3604.
  4. Prat, J. and De Nictolis, M. (2002) ‘Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion’, American Journal of Surgical Pathology, 26(9), pp. 1111-1128.
  5. National Cancer Institute (2026) Ovarian Low Malignant Potential Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-low-malignant-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.